Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 17:e32030.
doi: 10.1002/pbc.32030. Online ahead of print.

Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol

Catherine E Martin  1 , Madeleine B O'Keefe  2 , Taylor Gullickson  1 , Mira A Kohorst  2 , Anand Srinivasan  2 , Paul J Galardy  2 , Linda McAllister  2 , Jessica L Kalmes  2 , Alexis K Kuhn  1
Affiliations

Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol

Catherine E Martin et al. Pediatr Blood Cancer. .
No abstract available

PubMed Disclaimer

References

    1. S. Gupta, C. Wang, E. A. Raetz, et al., “Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,” Journal of Clinical Oncology 38, no. 17 (2020): 1897–1905, https://doi.org/10.1200/JCO.19.03024.
    1. R. J. Li, R. Jin, C. Liu, et al., “FDA Approval Summary: Calaspargase Pegol‐mknl for Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults,” Clinical Cancer Research 26, no. 2 (2020): 328–331, https://doi.org/10.1158/1078‐0432.CCR‐19‐1255.
    1. M. Sandley and J. Angus, “Asparaginase Therapy in Patients With Acute Lymphoblastic Leukemia: Expert Opinion on Use and Toxicity Management,” Leukemia & Lymphoma 64, no. 4 (2023): 776–787, https://doi.org/10.1080/10428194.2023.2171267.
    1. D. T. Teachey, M. Devidas, B. L. Wood, et al., “Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T‐Cell Acute Lymphoblastic Leukemia and Lymphoma,” Journal of Clinical Oncology 40, no. 19 (2022): 2106–2118, https://doi.org/10.1200/JCO.21.02678.
    1. K. P. Dunsmore, S. S. Winter, M. Devidas, et al., “Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T‐Cell Acute Lymphoblastic Leukemia,” Journal of Clinical Oncology 38, no. 28 (2020): 3282–3293, https://doi.org/10.1200/JCO.20.00256.

LinkOut - more resources